The COVID-19 pandemic produced a growth slowdown at pharmaceutical drug discounter GoodRx Holdings (NASDAQ: GDRX). If patients aren’t going to their doctors, they’re not going to need drug discounts. The increase in physical distancing also blunted the flu season, which further reduced the need for medications. In this video from Motley Fool Live, recorded on March 15, Fool.com Contributors Brian Orelli and Keith Speights discuss what outside factors could help GoodRx accelerate growth in the quarters to come.
Latest from Blog
Just as many Americans are wondering whether it’s safe to plan a summer vacation involving a…
Rising bond yields have sparked a rotation from growth to value stocks over the past two…
One of the most effective ways to make a lot of money in the stock market…
Autoimmune diseases, such as rheumatoid arthritis, atopic dermatitis, and psoriatic arthritis, offer a multibillion-dollar opportunity for…
On March 8, golf equipment giant Callaway (NYSE: ELY) finalized its merger with sports entertainment and…